{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:05:10Z","timestamp":1784268310327,"version":"3.55.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12357-x","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:28:50Z","timestamp":1784266130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies"],"prefix":"10.1007","volume":"53","author":[{"given":"Swapnil S.","family":"Sanap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-048X","authenticated-orcid":false,"given":"Krishna R.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma D.","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind J.","family":"Umekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"5","key":"12357_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(25)00003-7","volume":"13","author":"GBD 2021 Asthma and Allergic Diseases Collaborators","year":"2025","unstructured":"GBD 2021 Asthma and Allergic Diseases Collaborators (2025) Global, regional, and national burden of asthma and atopic dermatitis, 1990\u20132021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir Med 13(5):425\u2013446. https:\/\/doi.org\/10.1016\/S2213-2600(25)00003-7","journal-title":"Lancet Respir Med"},{"issue":"10440","key":"12357_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators (2024) Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet (London England) 403(10440):2204\u20132256. https:\/\/doi.org\/10.1016\/S0140-6736(24)00685-8","journal-title":"Lancet (London England)"},{"issue":"1","key":"12357_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pccm.2025.02.005","volume":"3","author":"Z Mao","year":"2025","unstructured":"Mao Z, Zhu X, Zheng P, Wang L, Zhang F, Chen L, Zhou L, Liu W, Liu H (2025) Global, regional, and national burden of asthma from 1990 to 2021: A systematic analysis of the global burden of disease study 2021. Chin Med J pulmonary Crit care Med 3(1):50\u201359. https:\/\/doi.org\/10.1016\/j.pccm.2025.02.005","journal-title":"Chin Med J pulmonary Crit care Med"},{"issue":"1","key":"12357_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12931-023-02475-6","volume":"24","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li Y, Gao Y, Fu Y, Lin J, Lei X, Zheng J, Jiang M (2023) Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir Res 24(1):169. https:\/\/doi.org\/10.1186\/s12931-023-02475-6","journal-title":"Respir Res"},{"issue":"1","key":"12357_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003144","volume":"12","author":"L Zhang","year":"2025","unstructured":"Zhang L, Jiang H, Yang G, Zhang J, Yuan S, Chen J, Tang M, Lin J, Yuan J, Yin Y (2025) Global, regional and national burden of asthma from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMJ Open Respir Res 12(1):e003144. https:\/\/doi.org\/10.1136\/bmjresp-2025-003144","journal-title":"BMJ Open Respir Res"},{"key":"12357_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/JAA.S418145","volume":"16","author":"APJ Rabe","year":"2023","unstructured":"Rabe APJ, Loke WJ, Gurjar K, Brackley A, Iii L-P, D. E (2023) Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma. J asthma allergy 16:1097\u20131113. https:\/\/doi.org\/10.2147\/JAA.S418145","journal-title":"J asthma allergy"},{"key":"12357_CR7","unstructured":"Asthma and Allergy Foundation of America (2025) Cost of asthma on society. https:\/\/aafa.org\/advocacy\/key-issues\/access-to-health-care\/cost-of-asthma-on-society\/"},{"issue":"2","key":"12357_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","volume":"56","author":"ME Kuruvilla","year":"2019","unstructured":"Kuruvilla ME, Lee FE, Lee GB (2019) Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol 56(2):219\u2013233. https:\/\/doi.org\/10.1007\/s12016-018-8712-1","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"12357_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaci.2025.03.008","volume":"156","author":"AL Fuhlbrigge","year":"2025","unstructured":"Fuhlbrigge AL, Sharma S (2025) Unraveling the heterogeneity of asthma: Decoding subtypes of asthma. J Allergy Clin Immunol 156(1):41\u201350. https:\/\/doi.org\/10.1016\/j.jaci.2025.03.008","journal-title":"J Allergy Clin Immunol"},{"key":"12357_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851940","volume":"13","author":"C Pelaia","year":"2022","unstructured":"Pelaia C, Heffler E, Crimi C, Maglio A, Vatrella A, Pelaia G, Canonica GW (2022) Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets. Front Pharmacol 13:851940. https:\/\/doi.org\/10.3389\/fphar.2022.851940","journal-title":"Front Pharmacol"},{"issue":"5","key":"12357_CR11","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jaci.2016.08.032","volume":"139","author":"W Liu","year":"2017","unstructured":"Liu W, Liu S, Verma M, Zafar I, Good JT, Rollins D, Groshong S, Gorska MM, Martin RJ, Alam R (2017) Mechanism of TH2\/TH17-predominant and neutrophilic TH2\/TH17-low subtypes of asthma. J Allergy Clin Immunol 139(5):1548\u20131558e4. https:\/\/doi.org\/10.1016\/j.jaci.2016.08.032","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"12357_CR12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01619-2023","volume":"63","author":"G Varricchi","year":"2024","unstructured":"Varricchi G, Brightling CE, Grainge C, Lambrecht BN, Chanez P (2024) Airway remodelling in asthma and the epithelium: on the edge of a new era. Eur Respir J 63(4):2301619. https:\/\/doi.org\/10.1183\/13993003.01619-2023","journal-title":"Eur Respir J"},{"issue":"2","key":"12357_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2022.100229","volume":"5","author":"O Bronte-Moreno","year":"2023","unstructured":"Bronte-Moreno O, Gonz\u00e1lez-Barcala FJ, Mu\u00f1oz-Gall X, Pueyo-Bastida A, Ramos-Gonz\u00e1lez J, Urrutia-Landa I (2023) Impact of air pollution on asthma: a scoping review. Open Respir Arch 5(2):100229. https:\/\/doi.org\/10.1016\/j.opresp.2022.100229","journal-title":"Open Respir Arch"},{"issue":"4","key":"12357_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","volume":"11","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW (2023) Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J allergy Clin Immunol Pract 11(4):1213\u20131220e2. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.043","journal-title":"J allergy Clin Immunol Pract"},{"issue":"1","key":"12357_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12016-025-09045-2","volume":"68","author":"L Sahnoon","year":"2025","unstructured":"Sahnoon L, Bajbouj K, Mahboub B, Hamoudi R, Hamid Q (2025) Targeting IL-13 and IL-4 in Asthma: Therapeutic Implications on Airway Remodeling in Severe Asthma. Clin Rev Allergy Immunol 68(1):44. https:\/\/doi.org\/10.1007\/s12016-025-09045-2","journal-title":"Clin Rev Allergy Immunol"},{"key":"12357_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.969243","volume":"9","author":"G Guida","year":"2022","unstructured":"Guida G, Bagnasco D, Carriero V, Bertolini F, Ricciardolo FLM, Nicola S, Brussino L, Nappi E, Paoletti G, Canonica GW, Heffler E (2022) Critical evaluation of asthma biomarkers in clinical practice. Front Med 9:969243. https:\/\/doi.org\/10.3389\/fmed.2022.969243","journal-title":"Front Med"},{"issue":"1","key":"12357_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4081\/mrm.2020.36","volume":"15","author":"E Heffler","year":"2020","unstructured":"Heffler E, Carpagnano GE, Favero E, Guida G, Maniscalco M, Motta A, Paoletti G, Rolla G, Baraldi E, Pezzella V, Piacentini G, Nardini S (2020) Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP\/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Multidisciplinary respiratory Med 15(1):36. https:\/\/doi.org\/10.4081\/mrm.2020.36","journal-title":"Multidisciplinary respiratory Med"},{"issue":"8","key":"12357_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/jpm15080370","volume":"15","author":"PF Lavere","year":"2025","unstructured":"Lavere PF, Phillips KM, Hanania NA, Adrish M (2025) Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review. J personalized Med 15(8):370. https:\/\/doi.org\/10.3390\/jpm15080370","journal-title":"J personalized Med"},{"issue":"7","key":"12357_CR19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s12276-021-00652-5","volume":"53","author":"QL Quoc","year":"2021","unstructured":"Quoc QL, Choi Y, Thi Bich TC, Yang EM, Shin YS, Park HS (2021) S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma. Exp Mol Med 53(7):1170\u20131179. https:\/\/doi.org\/10.1038\/s12276-021-00652-5","journal-title":"Exp Mol Med"},{"issue":"11","key":"12357_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100991","volume":"17","author":"SJ Kim","year":"2024","unstructured":"Kim SJ, Choi YJ, Han MY, Hwang IT, Baek HS (2024) Evaluating serum periostin and YKL-40 as biomarkers for airway remodeling and hyperresponsiveness in pediatric asthma. World Allergy Organ J 17(11):100991. https:\/\/doi.org\/10.1016\/j.waojou.2024.100991","journal-title":"World Allergy Organ J"},{"issue":"4","key":"12357_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.25259\/ANAMS_136_2025","volume":"61","author":"R Garg","year":"2025","unstructured":"Garg R (2025) Breaking the steroid barrier: Emerging biomarkers and targeted therapies for type 2-low asthma. Ann Natl Acad Med Sci (India) 61(4):329","journal-title":"Ann Natl Acad Med Sci (India)"},{"issue":"2","key":"12357_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaci.2021.10.035","volume":"149","author":"SN Georas","year":"2022","unstructured":"Georas SN, Wright RJ, Ivanova A, Israel E, LaVange LM, Akuthota P, Carr TF, Denlinger LC, Fajt ML, Kumar R, O\u2019Neal WK, Phipatanakul W, Szefler SJ, Aronica MA, Bacharier LB, Burbank AJ, Castro M, Alexander C, Bamdad L, Cardet J, PrecISE Study Team (2022) The Precision Interventions for Severe and\/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol 149(2):488\u2013516e9. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.035","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"12357_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071093","volume":"12","author":"K Porpodis","year":"2022","unstructured":"Porpodis K, Tsiouprou I, Apostolopoulos A, Ntontsi P, Fouka E, Papakosta D, Vliagoftis H, Domvri K (2022) Eosinophilic asthma, phenotypes-endotypes and current biomarkers of choice. J Pers Med 12(7):1093. https:\/\/doi.org\/10.3390\/jpm12071093","journal-title":"J Pers Med"},{"issue":"1","key":"12357_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41030-018-0051-0","volume":"4","author":"SZ Bosnic-Anticevich","year":"2018","unstructured":"Bosnic-Anticevich SZ, Cvetkovski B, Azzi EA, Srour P, Tan R, Kritikos V (2018) Identifying Critical Errors: Addressing Inhaler Technique in the Context of Asthma Management. Pulmonary therapy 4(1):1\u201312. https:\/\/doi.org\/10.1007\/s41030-018-0051-0","journal-title":"Pulmonary therapy"},{"issue":"1","key":"12357_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0710-y","volume":"19","author":"OS Usmani","year":"2018","unstructured":"Usmani OS, Lavorini F, Marshall J, Dunlop WCN, Heron L, Farrington E, Dekhuijzen R (2018) Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res 19(1):10. https:\/\/doi.org\/10.1186\/s12931-017-0710-y","journal-title":"Respir Res"},{"issue":"1","key":"12357_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","volume":"205","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP (2022) Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med 205(1):17\u201335. https:\/\/doi.org\/10.1164\/rccm.202109-2205PP","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"12357_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00248-2022","volume":"9","author":"Y Lee","year":"2023","unstructured":"Lee Y, Lee JH, Park SY, Lee JH, Kim JH, Kim HJ, Kim SH, Chung KF, Song WJ (2023) Roles of real-world evidence in severe asthma treatment: challenges and opportunities. ERJ Open Res 9(2):00248\u20132022. https:\/\/doi.org\/10.1183\/23120541.00248-2022","journal-title":"ERJ Open Res"},{"issue":"1","key":"12357_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4168\/aair.2024.16.1.1","volume":"16","author":"SR Kim","year":"2024","unstructured":"Kim SR (2024) Next-Generation Therapeutic Approaches for Uncontrolled Asthma: Insights Into the Heterogeneity of Non-Type 2 Inflammation. Allergy Asthma Immunol Res 16(1):1\u20135. https:\/\/doi.org\/10.4168\/aair.2024.16.1.1","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"12357_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/jpm12010066","volume":"12","author":"Y Gautam","year":"2022","unstructured":"Gautam Y, Johansson E, Mersha TB (2022) Multi-Omics Profiling Approach to Asthma: An Evolving Paradigm. J personalized Med 12(1):66. https:\/\/doi.org\/10.3390\/jpm12010066","journal-title":"J personalized Med"},{"issue":"3","key":"12357_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/MCP.0000000000001065","volume":"30","author":"FT Canaday","year":"2024","unstructured":"Canaday FT, Georas SN, Croft DP (2024) Examining the impact of air pollution, climate change, and social determinants of health on asthma and environmental justice. Curr Opin Pulm Med 30(3):276\u2013280. https:\/\/doi.org\/10.1097\/MCP.0000000000001065","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"12357_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12356","volume":"14","author":"XL Song","year":"2024","unstructured":"Song XL, Liang J, Lin SZ, Xie YW, Ke CH, Ao D, Lu J, Chen XM, He YZ, Liu XH, Li W (2024) Gut-lung axis and asthma: a historical review on mechanism and future perspective. Clin Transl Allergy 14(5):e12356. https:\/\/doi.org\/10.1002\/clt2.12356","journal-title":"Clin Transl Allergy"},{"key":"12357_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1703989","volume":"6","author":"I Orzo\u0142ek","year":"2025","unstructured":"Orzo\u0142ek I, Kowalczyk P, Rybka-Fr\u0105czek A, Storman M, D\u0105browska M (2025) Thymic stromal lymphopoietin expression in different biological specimens in asthma: a systematic review and meta-analysis. Front Allergy 6:1703989. https:\/\/doi.org\/10.3389\/falgy.2025.1703989","journal-title":"Front Allergy"},{"key":"12357_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3690628","author":"H Kankaanranta","year":"2016","unstructured":"Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P (2016) Emerging comorbidities in adult asthma: risks, clinical associations, and mechanisms. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2016\/3690628","journal-title":"Mediators Inflamm"},{"issue":"3","key":"12357_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","volume":"157","author":"N Schoettler","year":"2020","unstructured":"Schoettler N, Strek ME (2020) Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine. Chest 157(3):516\u2013528. https:\/\/doi.org\/10.1016\/j.chest.2019.10.009","journal-title":"Chest"},{"key":"12357_CR35","volume-title":"StatPearls","author":"NR Abosamak","year":"2025","unstructured":"Abosamak NR, Patel P, Shahin MH (2025) Beta2-Receptor Agonists and Antagonists. StatPearls. StatPearls Publishing"},{"key":"12357_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8881895","author":"DP Tashkin","year":"2021","unstructured":"Tashkin DP, Ohar JA, Koltun A, Allan R, Ward JK (2021) The role of ICS\/LABA fixed-dose combinations in the treatment of asthma and COPD: bioequivalence of a generic fluticasone propionate-salmeterol device. Pulm Med. https:\/\/doi.org\/10.1155\/2021\/8881895","journal-title":"Pulm Med"},{"key":"12357_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221116997","volume":"16","author":"CM Averell","year":"2022","unstructured":"Averell CM, Lalibert\u00e9 F, Germain G, Duh MS, Rousculp MD, MacKnight SD, Slade DJ (2022) Impact of adherence to treatment with inhaled corticosteroids\/long-acting \u03b2-agonists on asthma outcomes in the United States. Ther Adv Respir Dis 16:17534666221116997. https:\/\/doi.org\/10.1177\/17534666221116997","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"12357_CR38","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaip.2024.01.011","volume":"12","author":"JG Krings","year":"2024","unstructured":"Krings JG, Beasley R (2024) The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today. J allergy Clin Immunol Pract 12(4):870\u2013879. https:\/\/doi.org\/10.1016\/j.jaip.2024.01.011","journal-title":"J allergy Clin Immunol Pract"},{"key":"12357_CR39","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 21700, Beclomethasone Dipropionate. Retrieved February 10, 2026, from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Beclomethasone-Dipropionate"},{"key":"12357_CR40","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 5281004, Budesonide. Retrieved February 10, 2026, from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Budesonide"},{"key":"12357_CR41","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 444036, Fluticasone Propionate. Retrieved February 10, 2026, from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Fluticasone-Propionate"},{"key":"12357_CR42","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 441336, Mometasone Furoate. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Mometasone-Furoate"},{"key":"12357_CR43","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 6918155, Ciclesonide. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ciclesonide"},{"key":"12357_CR44","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 6436, Triamcinolone Acetonide. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Triamcinolone-Acetonide"},{"key":"12357_CR45","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 5152, Salmeterol. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Salmeterol"},{"key":"12357_CR46","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 3410, Formoterol. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Formoterol"},{"key":"12357_CR47","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 6918554, Indacaterol. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Indacaterol"},{"key":"12357_CR48","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 11504295, Olodaterol. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Olodaterol"},{"key":"12357_CR49","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 56841116, Budesonide-formoterol mixt. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Budesonide-formoterol-mixt"},{"key":"12357_CR50","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 71300723, Fluticasone propionate\/salmeterol. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Fluticasone-propionate_salmeterol"},{"issue":"4","key":"12357_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.18553\/jmcp.2016.22.4.316","volume":"22","author":"E Yip","year":"2016","unstructured":"Yip E, Karimi S, Pien LT (2016) Evaluation of a therapeutic interchange from fluticasone\/salmeterol to mometasone\/formoterol in patients with chronic obstructive pulmonary disease. J Manag Care Spec Pharm 22(4):316\u2013323. https:\/\/doi.org\/10.18553\/jmcp.2016.22.4.316","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"12357_CR52","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/bcp.13847","volume":"85","author":"D Singh","year":"2019","unstructured":"Singh D, van den Berg F, Leaker B, Corradi M, Jabbal S, Collarini S, Mongelli V, Santoro L, Piccinno A, Biondaro S, Lipworth B (2019) Comparison of the effect of beclometasone\/formoterol in asthma patients after methacholine-induced bronchoconstriction: a noninferiority study using metered dose vs. dry powder inhaler. Br J Clin Pharmacol 85(4):729\u2013736. https:\/\/doi.org\/10.1111\/bcp.13847","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"12357_CR53","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/02770903.2024.2330485","volume":"61","author":"A Kumar","year":"2024","unstructured":"Kumar A, Jain MK, Barge VB, Kumar RS, Gupta N, Yadav H, Pal A, Redkar VE, Mondal A, Rathore RK, Daultani P, Jaiswal A, Mehta RT (2024) Efficacy and safety of Once-Daily Vilanterol\/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study. J asthma: official J Association Care Asthma 61(10):1181\u20131189. https:\/\/doi.org\/10.1080\/02770903.2024.2330485","journal-title":"J asthma: official J Association Care Asthma"},{"issue":"5","key":"12357_CR54","first-page":"364","volume":"121","author":"S Dubin","year":"2024","unstructured":"Dubin S, Patak P, Jung D (2024) Update on Asthma Management Guidelines. Mo Med 121(5):364\u2013367","journal-title":"Mo Med"},{"issue":"10","key":"12357_CR55","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1097\/MS9.0000000000002507","volume":"86","author":"M Aliyali","year":"2024","unstructured":"Aliyali M, Abedi S, Sharifpour A, Ghadirzadeh E, Fattahi M, Yazdani Charati J, Mehravaran H (2024) Effects of oral montelukast on pulmonary function and clinical symptoms in acute asthma exacerbations: a randomized, double-blind, placebo-controlled trial. Annals of medicine and surgery (2012) 86(10):5837\u20135843. https:\/\/doi.org\/10.1097\/MS9.0000000000002507","journal-title":"Annals of medicine and surgery (2012)"},{"key":"12357_CR56","volume-title":"StatPearls","author":"P Patel","year":"2025","unstructured":"Patel P, Sharma S (2025) Bronchodilators. StatPearls. StatPearls Publishing"},{"key":"12357_CR57","volume-title":"StatPearls","author":"DB Johnson","year":"2024","unstructured":"Johnson DB, Merrell BJ, Bounds CG (2024) Albuterol. StatPearls. StatPearls Publishing"},{"key":"12357_CR58","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 123600, (-)-Salbutamol. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Levalbuterol"},{"key":"12357_CR59","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 5403, Terbutaline. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Terbutaline"},{"key":"12357_CR60","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 6540473, Montelukast, (S)-. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Montelukast_-_S"},{"key":"12357_CR61","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 5717, Zafirlukast. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Zafirlukast"},{"key":"12357_CR62","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 60490, Zileuton. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Zileuton"},{"key":"12357_CR63","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for CID 657308. Retrieved April 15, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/ipratropium-bromide"},{"key":"12357_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101333","volume":"46","author":"T Boonpiyathad","year":"2019","unstructured":"Boonpiyathad T, S\u00f6zener ZC, Satitsuksanoa P, Akdis CA (2019) Immunologic mechanisms in asthma. Semin Immunol 46:101333. https:\/\/doi.org\/10.1016\/j.smim.2019.101333","journal-title":"Semin Immunol"},{"key":"12357_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.839011","volume":"13","author":"Y Gon","year":"2022","unstructured":"Gon Y, Maruoka S, Mizumura K (2022) Omalizumab and IgE in the control of severe allergic asthma. Front Pharmacol 13:839011. https:\/\/doi.org\/10.3389\/fphar.2022.839011","journal-title":"Front Pharmacol"},{"issue":"2","key":"12357_CR66","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00625-2024","volume":"11","author":"C Kyriakopoulos","year":"2025","unstructured":"Kyriakopoulos C, Papadopoulou E, Potonos D, Exarchos K, Beris E, Aggelopoulou C, Tryfon S, Gogali A, Kostikas K (2025) Effectiveness of anti-IL-5\/5R\u03b1 biologics in severe asthma in real-world studies: a systematic review and meta-analysis. ERJ Open Res 11(2):00625\u20132024. https:\/\/doi.org\/10.1183\/23120541.00625-2024","journal-title":"ERJ Open Res"},{"key":"12357_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1631321","volume":"16","author":"OZ Ameer","year":"2025","unstructured":"Ameer OZ, Mansour GK, Al-Amoudi RS, Abu-Owaimer FM (2025) Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness. Front Pharmacol 16:1631321. https:\/\/doi.org\/10.3389\/fphar.2025.1631321","journal-title":"Front Pharmacol"},{"issue":"1","key":"12357_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.alit.2022.11.006","volume":"72","author":"M Kurihara","year":"2023","unstructured":"Kurihara M, Kabata H, Irie M, Fukunaga K (2023) Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma. Allergology international: official J Japanese Soc Allergology 72(1):24\u201330. https:\/\/doi.org\/10.1016\/j.alit.2022.11.006","journal-title":"Allergology international: official J Japanese Soc Allergology"},{"issue":"5","key":"12357_CR69","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","volume":"151","author":"AT Akenroye","year":"2023","unstructured":"Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC, Keet CA, Jackson JW (2023) Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol 151(5):1269\u20131276. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.020","journal-title":"J Allergy Clin Immunol"},{"key":"12357_CR70","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for Omalizumab. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Omalizumab"},{"key":"12357_CR71","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for Mepolizumab. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Mepolizumab"},{"key":"12357_CR72","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for Reslizumab. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Reslizumab"},{"key":"12357_CR73","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for Benralizumab. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Benralizumab"},{"key":"12357_CR74","unstructured":"National Center for Biotechnology Information (2026) PubChem Compound Summary for Dupilumab. Retrieved February 10, 2026 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dupilumab"},{"key":"12357_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14937","volume":"8","author":"K Verstraete","year":"2017","unstructured":"Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, Vandenberghe I, Pauwels K, Tavernier J, Lambrecht BN, Hammad H, De Winter H, Beyaert R, Lippens G, Savvides SN (2017) Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun 8:14937. https:\/\/doi.org\/10.1038\/ncomms14937","journal-title":"Nat Commun"},{"issue":"5","key":"12357_CR76","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/all.15986","volume":"79","author":"M Caminati","year":"2024","unstructured":"Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, Lommatzsch M, Martin N, Matucci A, Nasser SM, Pavord ID, Domingo C (2024) Tezepelumab in patients with allergic and eosinophilic asthma. Allergy 79(5):1134\u20131145. https:\/\/doi.org\/10.1111\/all.15986","journal-title":"Allergy"},{"issue":"20","key":"12357_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126658","volume":"29","author":"M Zak","year":"2019","unstructured":"Zak M, Dengler HS, Rajapaksa NS (2019) Inhaled Janus kinase (JAK) inhibitors for the treatment of asthma. Bioorg Med Chem Lett 29(20):126658. https:\/\/doi.org\/10.1016\/j.bmcl.2019.126658","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"12357_CR78","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.anai.2021.08.416","volume":"127","author":"F Abbas","year":"2021","unstructured":"Abbas F, Georas S, Cai X, Khurana S (2021) Asthma biologics: Real-world effectiveness, impact of switching biologics, and predictors of response. Annals allergy asthma immunology: official publication Am Coll Allergy Asthma Immunol 127(6):655\u2013660e1. https:\/\/doi.org\/10.1016\/j.anai.2021.08.416","journal-title":"Annals allergy asthma immunology: official publication Am Coll Allergy Asthma Immunol"},{"issue":"4","key":"12357_CR79","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","volume":"120","author":"MD Howell","year":"2018","unstructured":"Howell MD, Fitzsimons C, Smith PA (2018) JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. Annals allergy asthma immunology: official publication Am Coll Allergy Asthma Immunol 120(4):367\u2013375. https:\/\/doi.org\/10.1016\/j.anai.2018.02.012","journal-title":"Annals allergy asthma immunology: official publication Am Coll Allergy Asthma Immunol"},{"key":"12357_CR80","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241254980","volume":"18","author":"T Inoue","year":"2024","unstructured":"Inoue T, Isogai S, Yamamoto N, Hiramatsu N, Niwa Y, Takahashi H, Kimura Y, Horiguchi T, Goto Y, Hashimoto N, Imaizumi K (2024) Safety and efficacy of bronchial thermoplasty in refractory asthma with severe obstructive respiratory dysfunction. Ther Adv Respir Dis 18:17534666241254980. https:\/\/doi.org\/10.1177\/17534666241254980","journal-title":"Ther Adv Respir Dis"},{"key":"12357_CR81","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/JAA.S200912","volume":"12","author":"NC Thomson","year":"2019","unstructured":"Thomson NC (2019) Recent developments in bronchial thermoplasty for severe asthma. J Asthma Allergy 12:375\u2013387. https:\/\/doi.org\/10.2147\/JAA.S200912","journal-title":"J Asthma Allergy"},{"issue":"9","key":"12357_CR82","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.3390\/jcm14093153","volume":"14","author":"N Faria","year":"2025","unstructured":"Faria N, Costa MI, Fernandes AL, Fernandes A, Fernandes B, Machado DC, Machado F, Sim\u00e3o L, Ribeiro L, Ferreira L, Boaventura R, Lima R, Ferreira J (2025) Biologic Therapies for Severe Asthma: Current Insights and Future Directions. J Clin Med 14(9):3153. https:\/\/doi.org\/10.3390\/jcm14093153","journal-title":"J Clin Med"},{"issue":"7","key":"12357_CR83","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/resp.13527","volume":"24","author":"C Moses","year":"2019","unstructured":"Moses C, Kaur P (2019) Applications of CRISPR systems in respiratory health: entering a new \u201cred pen\u201d era in genome editing. Respirology (Carlton, Vic.) 24(7):628\u2013637. https:\/\/doi.org\/10.1111\/resp.13527","journal-title":"Respirology (Carlton, Vic.)"},{"key":"12357_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114690","volume":"192","author":"P Luschnig","year":"2021","unstructured":"Luschnig P, Kienzl M, Roula D, Pilic J, Atallah R, Heinemann A, Sturm EM (2021) The JAK1\/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Biochem Pharmacol 192:114690. https:\/\/doi.org\/10.1016\/j.bcp.2021.114690","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"12357_CR85","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/02770903.2017.1337789","volume":"55","author":"RM Niven","year":"2018","unstructured":"Niven RM, Simmonds MR, Cangelosi MJ, Tilden DP, Cottrell S, Shargill NS (2018) Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma. J asthma: official J Association Care Asthma 55(4):443\u2013451. https:\/\/doi.org\/10.1080\/02770903.2017.1337789","journal-title":"J asthma: official J Association Care Asthma"},{"issue":"8","key":"12357_CR86","doi-asserted-by":"publisher","DOI":"10.71150\/jm.2504012","volume":"63","author":"H Hyeon","year":"2025","unstructured":"Hyeon H, Hwang S, Luo Y, Shin E, Yeom JH, Kim HM, Ryu M, Lee K (2025) CRISPR-Cas technologies: emerging tools from research to clinical application. Journal of microbiology (Seoul, Korea) 63(8):e2504012. https:\/\/doi.org\/10.71150\/jm.2504012","journal-title":"Journal of microbiology (Seoul, Korea)"},{"key":"12357_CR87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4939-9798-5_7","volume":"2059","author":"R Kandil","year":"2020","unstructured":"Kandil R, Xie Y, Mehta A, Merkel O (2020) A Method for Targeted Nonviral siRNA Delivery in Cancer and Inflammatory Diseases. Methods Mol biology (Clifton N J) 2059:155\u2013166. https:\/\/doi.org\/10.1007\/978-1-4939-9798-5_7","journal-title":"Methods Mol biology (Clifton N J)"},{"issue":"1","key":"12357_CR88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4168\/aair.2020.12.1.4","volume":"12","author":"S Taka","year":"2020","unstructured":"Taka S, Tzani-Tzanopoulou P, Wanstall H, Papadopoulos NG (2020) MicroRNAs in Asthma and Respiratory Infections: Identifying Common Pathways. Allergy Asthma Immunol Res 12(1):4\u201323. https:\/\/doi.org\/10.4168\/aair.2020.12.1.4","journal-title":"Allergy Asthma Immunol Res"},{"issue":"21\u201322","key":"12357_CR89","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1089\/hum.2023.078","volume":"34","author":"YA Huang","year":"2023","unstructured":"Huang YA, Chen JC, Chiang PC, Chen LC, Kuo ML (2023) Adeno-Associated Viral Vector-Delivered Pannexin-1 Mimetic Peptide Alleviates Airway Inflammation in an Allergen-Sensitized Mouse Model. Hum Gene Ther 34(21\u201322):1107\u20131117. https:\/\/doi.org\/10.1089\/hum.2023.078","journal-title":"Hum Gene Ther"},{"issue":"1","key":"12357_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.52793\/JSCR.2025.6(1)-69","volume":"6","author":"DP Ferreira","year":"2025","unstructured":"Ferreira DP, Silvaa ALD, Morales MM (2025) Advances in Gene Therapy for Respiratory and Renal Diseases. J Stem Cell Res 6(1):1\u201323. https:\/\/doi.org\/10.52793\/JSCR.2025.6(1)-69","journal-title":"J Stem Cell Res"},{"issue":"163","key":"12357_CR91","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0176-2021","volume":"31","author":"WW Busse","year":"2022","unstructured":"Busse WW, Kraft M (2022) Current unmet needs and potential solutions to uncontrolled asthma. Eur Respir Rev 31(163):210176. https:\/\/doi.org\/10.1183\/16000617.0176-2021","journal-title":"Eur Respir Rev"},{"issue":"3","key":"12357_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100520","volume":"14","author":"J S\u00e1nchez","year":"2021","unstructured":"S\u00e1nchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gomez C, Amaya D, Cardona R (2021) IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J 14(3):100520. https:\/\/doi.org\/10.1016\/j.waojou.2021.100520","journal-title":"World Allergy Organ J"},{"key":"12357_CR93","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S547261","author":"P Han","year":"2026","unstructured":"Han P, Wang L (2026) Effects of ICS\u2009+\u2009LABA combination therapy on asthma control: an observational study in real-world settings. Ther Clin Risk Manag. https:\/\/doi.org\/10.2147\/TCRM.S547261","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"12357_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101483","volume":"69","author":"VH Patel","year":"2023","unstructured":"Patel VH, Thannir S, Dhanani M, Augustine I, Sandeep SL, Mehadi A, Avanthika C, Jhaveri S (2023) Current limitations and recent advances in the management of asthma. Disease-a-month\u202f: DM 69(7):101483. https:\/\/doi.org\/10.1016\/j.disamonth.2022.101483","journal-title":"Disease-a-month : DM"},{"issue":"11","key":"12357_CR95","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/all.13874","volume":"74","author":"M Ekstr\u00f6m","year":"2019","unstructured":"Ekstr\u00f6m M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C (2019) Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy 74(11):2181\u20132190. https:\/\/doi.org\/10.1111\/all.13874","journal-title":"Allergy"},{"issue":"1","key":"12357_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/25310429.2025.2532973","volume":"31","author":"KEJ H\u00e5kansson","year":"2025","unstructured":"H\u00e5kansson KEJ, Ibsen R, Krogh NS, Soendergaard MB, Hansen S, Bjerrum A-S (2025) Financial burden of productivity loss in severe asthma and impact of biologic therapy. Pulmonology 31(1):2532973. https:\/\/doi.org\/10.1080\/25310429.2025.2532973","journal-title":"Pulmonology"},{"issue":"2","key":"12357_CR97","doi-asserted-by":"publisher","first-page":"e2556757","DOI":"10.1001\/jamanetworkopen.2025.56757","volume":"9","author":"T Pham","year":"2026","unstructured":"Pham T, Barker AR, Eisenstein SA et al (2026) Costs of single maintenance and reliever therapy vs traditional therapy for asthma. JAMA Netw Open 9(2):e2556757. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.56757","journal-title":"JAMA Netw Open"},{"issue":"1","key":"12357_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003867","volume":"13","author":"KEJ H\u00e5kansson","year":"2026","unstructured":"H\u00e5kansson KEJ, Ibsen R, Krogh NS, S\u00f8ndergaard MB, Hansen S, Bjerrum AS, von B\u00fclow A, Hilberg O, L\u00f8kke A, Bonnesen B, Kappel ME, Johansson SL, Dongo L, Borup MB, Vijdea R, Rasmussen LM, Schmid JM, Ulrik CS, Porsbjerg C (2026) Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis. BMJ Open Respir Res 13(1):e003867. https:\/\/doi.org\/10.1136\/bmjresp-2025-003867","journal-title":"BMJ Open Respir Res"},{"issue":"9","key":"12357_CR99","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1080\/02770903.2023.2183407","volume":"60","author":"SK Veettil","year":"2023","unstructured":"Veettil SK, Vincent V, Shufelt T, Behan E, Syeed MS, Thakkinstian A, Young DC, Chaiyakunapruk N (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. J asthma: official J Association Care Asthma 60(9):1702\u20131714. https:\/\/doi.org\/10.1080\/02770903.2023.2183407","journal-title":"J asthma: official J Association Care Asthma"},{"issue":"7","key":"12357_CR100","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/alr.23344","volume":"14","author":"VK Rathi","year":"2024","unstructured":"Rathi VK, Soler ZM, Schlosser RJ, Workman AD, Chapurin N, Rowan NR, Dusetzina SB (2024) The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma. Int forum allergy rhinology 14(7):1261\u20131265. https:\/\/doi.org\/10.1002\/alr.23344","journal-title":"Int forum allergy rhinology"},{"issue":"1","key":"12357_CR101","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01357-2024","volume":"65","author":"AHY Chan","year":"2025","unstructured":"Chan AHY, De Keyser HH, Horne R, Szefler SJ (2025) Viewpoint: defining adherence phenotype and endotypes to personalise asthma management. Eur Respir J 65(1):2401357. https:\/\/doi.org\/10.1183\/13993003.01357-2024","journal-title":"Eur Respir J"},{"issue":"1","key":"12357_CR102","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12890-024-02995-x","volume":"24","author":"AA Alqarni","year":"2024","unstructured":"Alqarni AA, Aldhahir AM, Siraj RA, Alqahtani JS, Alghamdi DA, Alghamdi SK, Alamoudi AA, Mohtaseb MA, Majrshi M, AlGarni AA, Badr OI, Alwafi H (2024) Asthma medication adherence, control, and psychological symptoms: a cross-sectional study. BMC Pulm Med 24(1):189. https:\/\/doi.org\/10.1186\/s12890-024-02995-x","journal-title":"BMC Pulm Med"},{"issue":"11","key":"12357_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101132","volume":"18","author":"S Liu","year":"2025","unstructured":"Liu S, Lin Z, You L, Zhou J, Yang Q, Hu Z, Liang Y, Sun B (2025) Multi-omics identifies severe asthma endotypes linked to Streptococcus dysbiosis and lipid metabolic dysregulation. World Allergy Organ J 18(11):101132. https:\/\/doi.org\/10.1016\/j.waojou.2025.101132","journal-title":"World Allergy Organ J"},{"issue":"1","key":"12357_CR104","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2169\/internalmedicine.5004-24","volume":"65","author":"T Harada","year":"2026","unstructured":"Harada T, Inui G, Takata M, Okazaki R, Yamaguchi K, Yamasaki A (2026) Recent Advances and New Therapeutic Goals in the Management of Severe Asthma. Intern Med (Tokyo Japan) 65(1):23\u201331. https:\/\/doi.org\/10.2169\/internalmedicine.5004-24","journal-title":"Intern Med (Tokyo Japan)"},{"issue":"4","key":"12357_CR105","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v14i4.7422","volume":"14","author":"ZJ Alameh","year":"2026","unstructured":"Alameh ZJ (2026) Precision medicine in severe asthma: practical phenotyping and evidence-based selection of biologic therapy. Med Res Arch 14(4):7422. https:\/\/doi.org\/10.18103\/mra.v14i4.7422","journal-title":"Med Res Arch"},{"issue":"1","key":"12357_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-025-00465-3","volume":"36","author":"F Braido","year":"2025","unstructured":"Braido F, Baiardini I, Barbaglia S, Palkonen S, Ruiz A, Tsiligianni I, Virchow JC, Winders T (2025) A guide for a patient-centric approach to asthma management: results of a European Delphi consensus programme. NPJ Prim Care Respir Med 36(1):2. https:\/\/doi.org\/10.1038\/s41533-025-00465-3","journal-title":"NPJ Prim Care Respir Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12357-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:28:55Z","timestamp":1784266135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12357-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12357"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12357-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors has any conflicts of interest regarding their financial and non-financial resources.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1185"}}